Dicerna Pharma (DRNA) Reports Q4 Loss of $0.58
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 27, 2020 4:05 PM ESTCompany Achieves Multiple Clinical and Corporate Development Milestones in 2019, Advancing Core Pipeline Candidates; Expanding and Progressing Existing Collaborative Programs; and Establishing New, High-Value Collaborations With Roche and Novo Nordisk A/S
Anticipated 2020 Milestones Include: First Nedosiran Multi-dose Data From PHYOX3 Trial; RG6346 Phase 1 Proof-of-Concept Data; Patient Dosing in Phase 1/2 Trial of DCR-A1AT; and Nedosiran PHYOX2 Pivotal Trial Last Patient Out
$348.9 Million in Cash, Cash Equivalents and Marketable Securities at Dec. 31, 2019; $375 Million in Upfront Payments Related to Roche and Novo Nordisk Collaborations Received in January 2020
... More
